Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Merck
Baxter
Johnson and Johnson
Dow
Moodys

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Patent: 10,124,038

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 10,124,038
Title:Modulators of syndecan-2 and uses thereof
Abstract: Modulators of syndecan-2, such as an antibody to syndecan-2 that cross-links syndecan-2 on the cell surface or a syndecan-2 polypeptide that interferes with syndecan-2 receptor binding, is used to regulate a Th17 mediated disease such as an autoimmune disease, fibrosis or cancer.
Inventor(s): Elliman; Stephen J. (Galway, IE), Barkley; Laura Rose (Galway, IE), Kavanaugh; Jack (Los Angeles, CA)
Assignee: ORBSEN THERAPEUTICS LIMITED (Galway, IE)
Application Number:15/074,681
Patent Claims:see list of patent claims

Details for Patent 10,124,038

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ORBSEN THERAPEUTICS LIMITED (Galway, IE) 2035-03-20 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ORBSEN THERAPEUTICS LIMITED (Galway, IE) 2035-03-20 RX Orphan search
Janssen Biotech SIMPONI ARIA golimumab INJECTABLE; INJECTION 125433 001 2013-07-18   Start Trial ORBSEN THERAPEUTICS LIMITED (Galway, IE) 2035-03-20 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Merck
AstraZeneca
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.